How institutional buyers think differently, why most GTM strategies fail in healthcare, and what works instead.
By Meghna Deshraj, Founder & CEO, Bullzeye Global Growth Partners | June 2026
You hired a growth team. Smart people. They know how to build demand gen engines, understand unit economics, can execute SaaS playbooks. They run the playbook.
Six months later, your pipeline is flat. Your healthcare customers ghost you. Your MedTech CMO is frustrated. You’re burning cash on channels that worked at your last company and nowhere here.
The problem is not incompetence. It’s vertical blindness.
The Market Split Happened. You’re Still Pretending It Didn’t.
There are two GTM universes now. They operate on different physics. Most GTM advice is built for one and silently breaks in the other.
DTC Universe: Urgency wins. Agitation, specificity, earned scarcity. The buyer scrolls their feed. You have three seconds. Speed and conviction and the dream buyer living in your copy. Volume plays. Test and iterate and kill what doesn’t move the needle in weeks.
Healthcare, MedTech, Life Sciences Universe: Credibility wins. The buyer is not scrolling. They’re evaluating risk. They’re checking with peers. They’re asking if you’ve worked with someone like them. Months-long consideration cycles. Regulatory adjacency matters. One misstep kills the entire campaign. Speed is not your advantage. The buyer needs evidence, not agitation.
Figure 1: The market split. DTC peaks early and plateaus. Institutional builds slowly, then compounds exponentially.
Same growth problem. Different solution. Most people see the problem and default to DTC because that’s what they know.
I see this pattern weekly. A founder or CMO says, “We launched a demand gen campaign. Cost per lead jumped. We’re not converting them.” Then we look at what they’re running. It’s high-temperature messaging in a clinic. Bold offer. Urgency and agitation. Landing on a physician buyer who needs clinical evidence before they move. The campaign is generating leads, not because it’s working, but because it’s cheap to generate leads when you’re not qualifying for institutional appetite. Every lead from that machine is tire-kicking. Volume with no conversion.
Activity masking as strategy.
The fix is not to run DTC slower. It’s to run institutional GTM entirely differently. That starts with understanding what your buyer actually needs to move.
Where Most GTM Strategies Break in Healthcare and MedTech
Let me be specific about the break points because specificity is where the diagnosis lives.
The Credibility Leak
You’re running paid ads to “CMOs at mid-market health systems.” The ad promises results, speed, ROI – all the DTC promises. A CMO clicks. They land on a site with case studies from fitness brands and e-commerce companies. No healthcare. No regulatory context. No mention of HIPAA, compliance, payer relationships. They feel sold to. They leave.
Figure 2: The credibility leak. Healthcare buyers need domain-specific proof before engagement.
The leak: You treated credibility as a nice-to-have instead of the fundamental buying signal. In healthcare, the buyer asks, “Has this person worked in this space before?” If the answer is not clear in the first thirty seconds, they’re gone. Not because your solution is bad. Because the risk of being wrong is too high. At Bullzeye, we work with healthcare and MedTech clients where one miscalibration erodes months of runway. A messaging miss costs more than a paid ads miss in DTC because the deal size is larger and the sell cycle is longer. You cannot afford to show up as a generalist.
The Channel Misfit
A MedTech founder tells me they’re running outbound email to orthopedic hospital procurement teams. Volume is strong. Reply rate is weak. They’re comparing it to their B2B SaaS benchmarks and thinking the campaign underperforms. But orthopedic procurement doesn’t evaluate vendors through email opens. They evaluate through peer validation, trade shows, and clinical advisory boards. The email is the wrong channel entirely. It’s not a conversion problem. It’s an architecture problem. You’re hunting for fish in a parking lot.
The pattern: Founders and CMOs apply their previous playbook without asking, “How does my specific buyer actually evaluate and move?” DTC works because the buyer self-qualifies. Institutional buyers are heterogeneous. A hospital administrator buys differently than a health plan. A pulmonologist buys differently than a hospital administrator. Same vertical, different buyer. Different evaluation criteria, different timelines, different skepticism.
The Proof Point Problem
“We have five case studies. Three are from SaaS, one from a healthtech startup, one from a regional clinic.” You’re hedging. Investors and buyers read hedging as, “We haven’t actually proven this in the segment we’re claiming to serve.”
In healthcare and MedTech, you need proof points from your specific buyer segment. If you’re selling to health systems, you need health systems as reference customers, not clinics. If you’re selling to payers, you need payers. The specificity is where trust lives. The proof point should answer: What was their starting state? What specific challenge did they have? What did implementation look like? What’s the outcome they’re measuring (not “saved 40% on costs” – that’s generic – but “urology department average time to diagnosis dropped from 60 days to 14 days, measured through EHR dashboards”)?
Specificity earns belief. Generality erodes it.
The Messaging Tempo Problem
A DTC campaign that works: problem-agitation-solution in six days. High temperature throughout. Bold offer. You’re moving the buyer from “I didn’t know this existed” to “I need this now.”
An institutional healthcare campaign that works: education, credibility, specification of fit over six weeks. Measured temperature. The buyer is asking different questions: “Is this FDA-cleared? Has anyone I trust used this? What does implementation look like? How does this integrate with our existing stack?” These are not fast questions.
Many teams try to compress the timeline. They run healthcare GTM like DTC on a slower calendar. Three-week nurture instead of three-day. But the fundamental architecture is still high-temperature, problem-solution, urgency-driven. That doesn’t work. The buyer is not uncertain about whether they need what you’re selling. They’re uncertain about whether you can deliver it with the specificity and safety their organization requires. Speed reads as recklessness. Authority and evidence reads as competence.
What Institutional GTM Actually Looks Like
Let me separate what works from what sounds like it should work.
Owned Distribution Over Purchased
In DTC, paid ads are the engine. You buy demand. In institutional healthcare, owned distribution is the edge. Relationships with key opinion leaders. Direct access to procurement teams through advisors. A content library that actually gets cited inside institutional networks. Your CEO or CMO visible on relevant panels and advisory boards.
Figure 3: The compounding moat. Paid ads win early and plateau. Owned distribution accelerates in year 2-3.
Why? Because institutional buyers validate before they buy. They call someone they know. They ask in a WhatsApp group. “Has anyone used this? What’s the implementation like?” Your ads don’t answer that question. Your network does. This is where speed actually matters – not speed to conversion, but speed to visibility within the segments that matter.
At Bullzeye, we build this through strategic advisory board placement, thought leadership in the right journals and conferences, speaker placement on institutional panels, and content that gets surfaced inside buyer communities. It costs more to build than a paid ads machine. It compounds faster once it’s built. The moat you build is not cost-per-lead. It’s that you’re the credible player. Every new prospect comes in warm because the previous customer referred them.
Proof Points That Actually Prove Something
Not five case studies across five verticals. Three case studies from your specific buyer segment. And they need to tell a specific story, not a generic one. The story should answer: What was their starting state? What specific challenge did they have? What did implementation actually look like? What’s the outcome they’re measuring? Not “they saved 40% on costs” – that’s generic and sounds made up. “Their urology department had 60-day average time to diagnosis. After implementing our platform, that dropped to 14 days. They measured it through their EHR dashboards.” That’s credible. That earns belief.
The Numbers That Actually Matter in Healthcare GTM
In healthcare, the metrics that prove repeatability, predictability, and efficiency are different from DTC. Most teams measure the wrong outcomes in healthcare and think they’re broken because the numbers don’t hit SaaS benchmarks.
DTC Metrics: CAC payback period, LTV:CAC ratio, blended CAC trend, cost per lead, trial-to-paid conversion.
Healthcare Metrics: Sales cycle length by buyer segment, close rate by segment, net dollar retention (because expansion revenue often comes from implementation success and strong reference calls to peers), win rate against named competitors in your target segment.
Figure 4: DTC vs. Healthcare metrics. What you measure determines what you optimize for.
The DTC metrics assume volume and velocity. The healthcare metrics assume precision and concentration. You’re measuring whether you can win a specific segment repeatably, not whether you can scale ad spend efficiently. Many teams measure DTC metrics in healthcare and think the numbers are broken. They’re not broken. You’re measuring the wrong outcomes.
CAC payback in healthcare might be 18 months because the deal size is larger (ACV $150K+) and the close cycle is 4-6 months. That’s not a problem. That’s the business. A sales cycle of 120-180 days is normal. Close rates of 20-30% across a well-qualified pipeline are healthy. The metric that matters is whether you can repeat this in your target segment reliably. When institutions buy, they buy slowly, but they buy committed.
The question is not: How fast can I convert? The question is: Can I convert my target segment predictably?
How Bullzeye Builds Institutional GTM
Let me be concrete about how this works in practice because pattern recognition without execution is just theory.
Step 1: Map your buyer heterogeneity. Not “hospital administrators.” Which hospital administrators? Teaching hospitals or community hospitals? Health systems of 5,000 beds or 100? Are you selling to the CMO, the CRO, the Chief Medical Information Officer? Each buys differently. Each has different evaluation criteria, different timelines, different skepticism.
Step 2: Build targeted strategy around how that buyer evaluates risk. Not a dashboard with seven channels. Three channels where we can own the narrative and build credibility. One might be owned media and thought leadership. One might be a strategic advisory program where you embed with key opinion leaders in that segment. One might be direct outreach through existing networks and references.
Step 3: Spec out what proof points actually move that buyer. What case study could we build from your current customers that would make a prospect nod? Not impressive case studies. Case studies that directly address the skepticism your specific buyer carries. If your buyer is a payer, they care about ROI, implementation complexity, and integration with existing systems. If your buyer is a hospital, they care about clinical validation, compliance, and change management.
Step 4: Sales messaging. Not about what you offer, but about what specific implementation and outcome your buyer should expect. Walk through the implementation timeline. Be specific about what their team needs to know. Show the evidence. This is where the sales rep becomes an educator, not a persuader.
Step 5: Measure outcomes, not activities. Not “we booked 50 meetings.” Do those 50 meetings move the pipeline? What’s our win rate against that specific segment? Are reference calls happening? Are we getting inbound from that segment because someone referred us? Activity looks impressive in a slide. Outcomes move revenue.
The Organizational Shift This Requires
Here’s where most teams fail: They try to bolt institutional GTM onto a DTC team, or they hire an enterprise AE to sit inside a DTC organization. It doesn’t work because the incentives are misaligned.
DTC team gets evaluated on volume: meetings, trials, signups. Fast turnaround. Healthcare team needs to get evaluated on close rate and pipeline quality. Slower turnaround, higher confidence on each deal. Same organization. Opposite metrics. That conflict metastasizes.
At Bullzeye, we’ve seen this blow up enough times to know the fix: Separate your institutional GTM reporting from your DTC reporting. Different targets, different team leadership, different KPIs. The institutional team should not be evaluated on meeting count. They should be evaluated on pipeline progression and close rate. The DTC team should not be evaluated on healthcare metrics. They should be evaluated on cost per acquisition and payback. Only then do the incentives align with what the strategy actually requires.
Where You Likely Are Right Now
If you’re a DTC founder or early-stage healthcare company, you probably hired someone who came from SaaS or consumer. They know demand gen. They know channel testing. They know how to move the needle on acquisition cost. They’re running healthcare on a DTC calendar and metrics.
Your pipeline is flat. Your deals aren’t closing. Your CAC is too high. You’re wondering if healthcare is just a harder market. You’re asking if institutional buyers are slower, less responsive, more skeptical. You’re thinking about pivoting back to DTC because at least you know how to move that needle.
It’s not harder. It’s different. And different requires a different architecture. The team that gets this right first wins the segment.
The Bet
Here’s what I’m confident about from working with dozens of healthcare and MedTech teams: The winner in institutional GTM is not the team that moves fastest. It’s the team that moves with precision and credibility.
That team takes longer to build initial traction. But once traction hits, it sticks. Deals close. Customers refer. Your sales reps can sell on credibility and proof instead of persuasion. In DTC, your moat is speed and continuous optimization. In healthcare, your moat is that you’re the credible player. You’ve proven you understand this buyer. You’ve walked through their implementation. You’ve built relationships with their peers. Now every new prospect comes in warm because the previous customer referred them.
That’s a different growth curve. Steeper in year two than year one. Most of your competition will give up before they see it.
The question is whether you’re willing to build it differently. If you’re at a healthcare or MedTech company and your current GTM is built on DTC principles, you have an opening. Every competitor running the same model is probably frustrated too. The one that shifts to precision and credibility first wins the segment.
That shift starts with one simple discipline: Stop applying yesterday’s playbook to a different buyer. Get specific about who moves and build a strategy that earns belief instead of demanding it. The rest is execution.
Working with healthcare, MedTech, or life sciences buyers and your GTM is stuck? Bullzeye embeds alongside CMOs and growth leaders to rebuild GTM strategy for institutional buyers. We translate what works in one vertical to what actually moves revenue in yours. Let’s talk if the GTM is broken and the fix feels structural.
About the Author: Meghna Deshraj is founder and CEO of Bullzeye Global Growth Partners, a strategic advisory firm specializing in growth-stage healthcare, MedTech, and life sciences companies. Her background includes investor relations, marketing strategy, and business development for companies ranging from early-stage to Series B. She runs PMO and BD at Bullzeye, where nothing ships without verification of the claims underneath.
Sources & Expert Citations:
Kyle Poyar, Growth Unhinged – GTM strategy, SaaS pricing, product-led growth
Liz Christo, Stage 2 Capital – Early-stage B2B software investment and GTM expertise
Paul Irving, GTMfund – Early-stage SaaS GTM investment and platform development
Ivan Landabaso, JME Ventures & Startup Riders – Early-stage investing and startup growth strategy